Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study

JOURNAL ARTICLE published November 2021 in Respiratory Medicine and Research

Authors: T. Payen | J. Trédaniel | L. Moreau | S. Larivé | J. Le Treut | C. Nocent | S. Hominal | V. Grangeon | J.-L. Bizec | O. Molinier | D. Debieuvre